French pharmaceutical company Sanofi is investing €350m (CAD$500m) for the construction of a new vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario.
Sanofi expects the investment to strengthen the company’s Canadian operations and its commitment to advancing public health around the world.
Executive vice president and head of Sanofi Pasteur David Loew said: “Canada has a strong legacy in the research and development of vaccines.
“With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe.
“Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease.”
The new Toronto facility is one of the largest-ever investments by Sanofi in a single building.
The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand for five-component acellular pertussis (5-acP) antigen.
The new building will be completed in 2021 and it will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines.
Sanofi executive vice president of global industrial affairs Philippe Luscan said: “This project is one of the most important investments for the Sanofi global industrial network.
“It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world.”
Sanofi Pasteur’s Canadian facility was founded as the Connaught Antitoxin Laboratories and University Farm in 1917.
The Toronto site was home to the world’s first large-scale commercial insulin production and was the sole supplier of the diabetes treatment to Canadians until the 1980s.
The Canadian facility also produced an antitoxin for diphtheria and was also a partner in the eradication of polio in North America and smallpox around the world.